Ads
related to: survival food companies list
Search results
NIAID funds second year of Pluri's radiation therapy studies By Investing.com
Investing.com· 2 hours agoPluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm, has received continued funding from the...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 1 day agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
Main Street Ventures awards first grants of 2024 to Mimi’s Macros, Almost V’Gan, Common Kin -...
The Business Journals· 11 hours agoThe 12 recipients, which include a restaurant opening soon in downtown Cincinnati and a local meal...
DermaSensor COO on bringing skin cancer detection device to market - South Florida Business Journal
The Business Journals· 1 day agoAfter years of development, DermaSensor's handheld skin cancer detection tool is now in the hands of...
Promising HPV Cancer Treatment Advances in Clinical Trial By Investing.com
Investing.com· 2 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has reported...
What are CT utilities doing to prep for an expected severe hurricane season: It's business as usual.
Stamford Advocate· 4 hours agoProjections for what could be a historic hurricane season in Connecticut and along the rest of the...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 3 days agoA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company
Bob's discount campaign
Politico· 2 days agoCatalini: “New Jersey proposed Monday removing the bald eagle from its endangered species list, citing a rebound since more than four decades ago, when a single nesting pair ...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 3 days agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
A Lesson From History: AI Is Not Likely To Kill Jobs
Forbes· 4 days agoAI adoption in businesses is beginning to grow. According to McKinsey’s State of AI in Early 2024 survey, which was released last week, nearly three quarters of U.S. businesses are now using ...